Furthermore, chemo- and/or immunotherapy of MM, despite the risk of the development of refractoriness, is capable of reinforcing both PD-1 and CTLA-4 checkpoint expression, making them more attainable to the therapeutic inhibitors in RRMM. Here, CTLA4 is linked to Miyoshi myopathy.